Williams-Sonoma (WSM) Profit drops. Down to $16.26 from 52-week high of $34.81.
Nexmed (NEXM) Drug trial failure still pulling shares down. Dips to $.19 from 52-week high of $1.75.
Genaera (GENR) Several clinical trials suspended. Falls to $.82 from 52-week high of $3.09.
Neurogen (NRGN) Gets notice on Nasdaq delisting. Sells down to $.25 from 52-week high of $5.24.
Douglas A. McIntyre
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
